Viavi Solutions enters the week with a pointed contradiction at its core. The stock is down nearly 8% on the week to $49.28, erasing a chunk of the extraordinary post-earnings rally — yet insiders were selling aggressively into that strength, and options traders are now tilting toward calls rather than hedging.
The insider story is the most striking data point right now. CEO Oleg Khaykin sold more than 394,000 shares across three sessions from May 5 to May 8, collecting roughly $21 million at prices between $51 and $55. He was not alone — the General Counsel, Chief Strategy Officer, a Senior Vice President, and a director all sold during the same window. Over the 90 days tracked, net insider value sold exceeds $32 million. That kind of coordinated selling cluster, hitting immediately after a 21% single-day earnings pop on April 30, reads as opportunistic monetisation rather than a loss of conviction — but it is worth watching how quickly the stock absorbs the supply.
The lending market tells a much calmer story than the insider activity suggests. Short interest has been falling sharply: it dropped more than 33% over the past month to roughly 5.1% of the free float, unwinding from peak levels above 8% seen in early April. The borrow itself is nearly free at under 0.5%, and availability is extremely loose at 756% — meaning for every share currently borrowed short, there are roughly seven and a half more available to borrow. That is well above the 52-week low of 454%, confirming that short sellers are not under any pressure. The ORTEX short score of 40.5 is in the lower half of the scale and has drifted slightly lower over the week, consistent with shorts reducing exposure into price strength rather than building a new attack.
Options are sending a mildly bullish signal that cuts against the insider selling narrative. The put/call ratio has fallen to 0.38, about one standard deviation below its 20-day average of 0.43. That is near the lower range of recent readings — call-side demand has picked up relative to puts. With the 52-week PCR low near 0.02, there is plenty of room for the ratio to compress further, but the current tilt suggests options traders are not reaching for protection after the week's pullback.
The Street broadly upgraded its view on Viavi after the April 30 earnings release. Multiple firms — including UBS, Susquehanna, and Needham — doubled their price targets to the $60-$68 range, all within the past three weeks. The consensus target is now around $64, implying roughly 30% upside from current levels at $49. Valuation multiples have compressed meaningfully: the EV/EBITDA ratio has fallen five turns over the past month to around 30x, and the P/E has come in by four points to 46x. Both moves reflect the earnings beat flowing through, though the absolute levels remain elevated. The bull case centres on continued aerospace and defence momentum from positioning and navigation products, plus early-stage AI data centre tailwinds from the Spirent acquisition. Bears point to lab testing competition, a stretched hyperscale cycle, and execution risk on the 20% operating margin target.
Institutional flows added a layer of interest. T. Rowe Price added 9 million shares in Q1, becoming the third-largest holder at 8% of shares outstanding. Invesco and FMR also built new or materially larger positions in recent months. Whale Rock Capital Management entered with a full new stake of 3.5 million shares as of March 31. The accumulation at institutional level stands in some contrast to the executive-level selling, though the timing difference — most institutional filings reflect Q1 positioning, before the post-earnings move — is an important caveat.
Peers have also pulled back sharply this week. LITE fell 10%, INSG dropped 14%, and AAOI shed 9% — indicating the weakness is sector-wide rather than VIAV-specific. CIEN and ADTN held up comparatively better. With the next earnings event scheduled for August 6, the key question into summer is whether the aerospace and defence order pipeline — cited as the primary driver of the earnings beat — can sustain the pace that justified the target-price doubles on the Street.
See the live data behind this article on ORTEX.
Open VIAV on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
